A single blind, comparative, multicentre, randomized study of the efficacy and safety of Pegstim, solution for subcutaneous injection, 6 mg/0.6 mL (Cadila Healthcare Ltd., India), and Neulastim, solution for subcutaneous injection, 6 mg/0.6 mL (Amgen Manufacturing Limited, USA), in patients diagnosed with breast cancer who receive myelosuppressive chemotherapy.

Trial Profile

A single blind, comparative, multicentre, randomized study of the efficacy and safety of Pegstim, solution for subcutaneous injection, 6 mg/0.6 mL (Cadila Healthcare Ltd., India), and Neulastim, solution for subcutaneous injection, 6 mg/0.6 mL (Amgen Manufacturing Limited, USA), in patients diagnosed with breast cancer who receive myelosuppressive chemotherapy.

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Pegfilgrastim (Primary)
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Sponsors Rus Biopharm
  • Most Recent Events

    • 11 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top